Dear Friends and Supporters:

As President of Concern Foundation, I am proud to present our annual report reflecting our 2013 successes, including some highlights of the important work being accomplished by the cancer research scientists funded by Concern.

Since our inception in 1968, advancements in research science have taught us so much about cancer. Perhaps the most important discovery so far is that cancer is not a single disease, but rather hundreds of diseases, each one developing through various pathways with differing responses to available treatments. So while today millions of cancer patients are winning the battle with this disease, far too many others are not so fortunate; this is why we will continue our quest to conquer cancer for as long as necessary. Our board’s leadership remains steadfastly committed to Concern Foundation’s original “concern”: to provide salary support to further the careers of gifted young cancer researchers and put an end to all cancers in our lifetime.

We all know that there is still a long road ahead of us in unlocking the secrets of cancer, so we must continue to develop new avenues for reaching deeper into our community to raise all of the necessary funds to accomplish our mission. We believe strongly that with your support and the precision with which our Scientific Review Committee evaluates each grant proposal, we remain on the right path.

I hope that you continue to be inspired and committed to Concern Foundation after viewing our annual report. Concern funded researchers have been incredibly productive, and we are proud to play a small role in their successes. The independent audited financial report will give you some insight into how efficient we are in putting your donations to the microscope without wasteful spending on overhead.

For 45 years, Concern has been at the forefront of science focused on the body’s immune system and sustaining cancer immunology research. As Concern Foundation grows year after year, and with the incredible commitment of funders like you, we are closer than ever to fulfilling our mission to conquer this disease once and for all.

Sincerely,

Derek Alpert
President
WHAT

Concern Foundation’s mission is to further the careers of gifted young cancer researchers (Assistant Professor or equivalent) whose work shows great promise, but may not be sufficiently advanced enough in their careers to justify major funding from the government or other larger funding sources. We focus on funding innovative minds that have a slightly different perspective in attempting to solve the mystery of cancer.

WHY

“We have reached the point of diminishing returns with the available cancer therapies…it’s no longer acceptable in the 21st century to deliver more chemotherapy or radiation. New, novel therapies are necessary.” Scientific Review Committee Member, Laurence Cooper, perhaps said it best when he stated the importance of providing start up grants to young investigators. We believe that a unique approach to looking at cancer will continue to fuel progress and effective therapies in the treatment of cancer. For 46 years, Concern Foundation has made it possible to transform new ideas from the mind of a researcher into fruitful innovations in cancer research.

HOW

New grant proposals are accepted every two years and undergo a rigorous peer review process. Potential applicants are pre-screened with a Letter of Intent, which ensures that only qualified investigators complete the thorough and detailed grant application. Each application is then administratively reviewed. A primary and secondary review follows by Concern Foundation’s Scientific Review Committee. Those applications that advance through these stringent levels are then discussed in further detail at the biennial Scientific Review Committee meeting.

Concern Foundation strives to recruit a cross-section of new and established cancer researchers who comprise our renowned Scientific Review Committee. These exceptional men and women guide our grant review process and help us select the top researchers from a competitive pool of applicants.

Each grant recipient is awarded a $60,000 grant. Provided that sufficient progress is achieved in the first year, Concern awards a second year grant of $60,000. It is the Foundation’s hope that after two years of funding, Concern-sponsored researchers go on to publish their findings in major journals, obtain larger awards to further their work, and advance their positions at respected institutions across the United States and abroad.
Lifeng Xu Ph.D.
The Regents of the University of California (University of California Davis)
Type Of Cancer: Blood & Bone Marrow
Project Title: Characterizing the Role of TIN2 in Telomerase Activation

Matthew Pratt Ph.D.
USC/University of Southern California
Type Of Cancer: Breast, Lung, Prostate
Project Title: Cancer Metabolism and Protein Glycosylation
***This research grant is co-funded by the Save The Ta-tas Foundation

Thomas Fazzio PhD
University of Massachusetts Medical School
Type Of Cancer: Blood, Bone Marrow
Project Title: Function of the Mbd3/NURD chromatin remodeling complex in myeloid leukemias

Scott Welford Ph.D.
Case Western Reserve University - School of Medicine
Type Of Cancer: Kidney – Renal Cell
Project Title: Modulation of the tumor microenvironment by the MIF Signaling Program.

Niv Papo Ph.D.
Ben-Gurion University of the Negev
Type Of Cancer: Brain, Breast, Liver & Ovarian
Project Title: Developing Antagonistic Protein Ligands for Cancer Imaging and Therapy

Timothy Donahue M.D.
The Regents of the University of California, Los Angeles
Type Of Cancer: Pancreas
Project Title: Targeting The Immunosuppressive Activity of MDSC in Pancreatic Cancer

Xaralabos Varelas Ph.D.
Trustees of Boston University, B U Medical Campus
Type Of Cancer: Breast
Project Title: Defining polarity cues that control tumor initiation and progression

Sanaz Memarzadeh Ph.D., M.D.
The Regents of the University of California, Los Angeles
Type Of Cancer: Uterus
Project Title: Potential utility of a PARP inhibitor in targeting endometrial cancers

Erin Dickerson Ph.D.
University of Minnesota - Twin Cities
Type Of Cancer: Ovarian
Project Title: Targeted Approaches for Overcoming Drug Resistance in Ovarian Cancer

Dean Tantin Ph.D.
University of Utah
Type Of Cancer: Blood, Bone Marrow, Leukemia
Project Title: Control of myeloid leukemia self-renewal
***This research grant is co-funded by Wendy & Tom Nogradi

Sergei Koralov Ph.D.
New York University School of Medicine
Type Of Cancer: Leukemia, Lymphatic system, Skin- non-melanoma
Project Title: Stat3 in T cells: At the crossroads of inflammation and cancer

Weihang Chai Ph.D.
Washington State University
Type Of Cancer: Basic Research
Project Title: Function of CST in telomere maintenance and cancer cell growth

Matthew Strout M.D., Ph.D.
Yale University
Type Of Cancer: Blood, Lymph nodes, Non-Hodgkin’s Lymphoma
Project Title: The Role of Immune Diversification in Lymphomagenesis

Thomas Graeber Ph.D.
The Regents of the University of California, Los Angeles
Type Of Cancer: Melanoma
Project Title: Signaling changes that confer resistance to BRAF-targeted melanoma therapy

Jennifer Carew PhD
Univ of Texas Health Science Center at San Antonio
Type Of Cancer: Ovarian
Project Title: Targeting NAE: A New Strategy for Ovarian Cancer Therapy

Andrew Snow Ph.D.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Type Of Cancer: Blood, Bone marrow, Leukemia, Leukocytes, Non-Hodgkin’s Lymphoma, Spleen
Project Title: Differential signaling of oncogenic CARD11 mutants in lymphocytes

Boyi Gan Ph.D.
University of Texas M.D. Anderson Cancer Center
Type Of Cancer: Pancreas
Project Title: study the impact of FoxO reactivation on pancreatic cancer treatment
2013 SPECIAL GRANTS AWARDED BY CONCERN FOUNDATION

Anat Epstein
Pediatric Cancer – Brain Tumor
Children’s Hospital Los Angeles
Funding matched by Mrs. Mimi Feldman

The Adolescent and Young Adult Program at USC (AYA@USC)
Tissue Registry, Social Worker & Data Coordinator
USC Norris Comprehensive Cancer Center & Children’s Hospital Los Angeles
Co-funded by Marion Brucker Legacy Fund

Smita Bhatia, M.D.
Population Sciences – Secondary Cancer Development
City of Hope
Funding matched by the Teller & Shapiro Family

Lilli Yang
Concern Foundation Stem Cell Research Award
UCLA Broad Stem Cell Research Center
Co-funded by Wendy & Tom Nogradi
Dr. Yang and colleagues hope to provide a roadmap for future therapies designed to increase the number of iNKT cells in the blood, creating more “special forces” cells and increasing the body’s ability to fight off cancer.

“The potential for iNKT T cell receptor-based gene therapy is very exciting because it is very different from conventional T cell receptor-based gene therapy,” said Dr. Yang. The kind of iNKT T cell receptor gene therapy we are investigating could have universal application, treating many types of cancer and a large group of patients no matter what types of tumor they have. It holds tremendous promise for the future.”

Dr. Yang’s research has made incredible strides at a remarkable pace. As a result of her work funded by Concern, she is a recent recipient of the prestigious $2.3 million NIH Director’s New Innovator Award.

Anat Erdreich-Epstein, MD, PhD
Children’s Hospital Los Angeles

A GENE THAT IMPROVES BRAIN TUMOR RESPONSE TO THERAPY

The work supported by the Concern Foundation and Ms. Mimi Feldman has prompted interactions with two groups of brain tumor researchers from separate institutions, who have access to independent and non-overlapping expression microarray databases of tumors and survival data from patients with medulloblastoma and gliomas. As a result, these investigators are now collaborating with us on this project. They have contributed important clinical correlations to our first manuscript.

Lili Yang, PhD
University of California, Los Angeles

STEM CELL-ENGINEERED INVARIANT NATURAL KILLER T CELLS FOR CANCER IMMUNOTHERAPY

Lili Yang, PhD, was recruited to the UCLA Broad Stem Cell Research Center from Caltech in January 2013. Concern Foundation and one of its community partners, Save the Ta-tas Foundation, provided the much needed resources for Dr. Yang to initiate a project that will establish stem cell-engineered natural killer T cell therapy for cancer.

Our blood is comprised of blood stem cells, including special white blood cells called T cells, which serve as the “foot soldiers” of the immune system, attacking intruders that cause diseases. Among these is a smaller group of cells called invariant natural killer T cells (iNKT), which have a remarkable capacity to mount immediate and powerful responses to disease when activated, much like a special forces unit among the foot soldiers.

Dr. Yang’s project is developing a novel model system to genetically program human blood stem cells to become iNKT cells. With this knowledge, Dr. Yang and colleagues hope to provide a roadmap for future therapies designed to increase the number of iNKT cells in the blood, creating more “special forces” cells and increasing the body’s ability to fight off cancer.

We found that each third of PID1 had independent inhibitory activity and that the middle third was more inhibitory than the full length PID1 and the other two thirds. When we deleted thirds from the full length PID1 we found that PID1 with deletion of the middle third or the last third had similar activity to the full length protein, but that deleting the first (N-terminal) third caused loss of activity. This suggests that the inhibitory activity of PID1 lies in several of its domains, possibly via different mechanisms, and that there may be complex intramolecular interactions that regulate this activity. We are currently continuing to dissect the regions responsible for PID1’s activity in order to understand its molecular mechanism of action.

The postdoctoral fellow will build on these findings and continue to dissect the molecular mechanism of PID1. Once the region responsible for the inhibitory effect in PID1 and its function are known, it may be possible to model this knowledge for future therapeutic use.

The Children’s Center for Cancer and Blood Diseases remains ever grateful for the Concern Foundation’s generous support of the research we conduct and the children and families we serve. It is only through partnerships with philanthropic organizations like Concern that we can achieve our mission to discover cures for devastating pediatric brain tumors while serving the needs of our patients. Our work on PID1 has been generously supported for the past two years in part through funds from Ms. Mimi Feldman and the Concern Foundation.

Specific Aim: Determine which cellular processes contribute to the decreased growth of medulloblastoma cells that have high PID1.

During our first year we reported that medulloblastoma cell lines engineered to express PID1 had decreased colony formation, indicating growth inhibition by PID1. The inhibition was due to both decreased proliferation and increased cell death. Using a mutant of PID1 we found that the growth inhibition was not mediated via its phosphotyrosine binding (PTB) domain, suggesting that the function of PID1 lay in a different domain of the gene to which function has not yet been assigned.

In the second year we tested six mutants of PID1, each comprising a third of PID1, as well as deletion mutants of PID1.

The postdoctoral fellow will build on these findings and continue to dissect the molecular mechanism of PID1. Once the region responsible for the inhibitory effect in PID1 and its function are known, it may be possible to model this knowledge for future therapeutic use.

The work supported by the Concern Foundation and Ms. Mimi Feldman has prompted interactions with two groups of brain tumor researchers from separate institutions, who have access to independent and non-overlapping expression microarray databases of tumors and survival data from patients with medulloblastoma and gliomas. As a result, these investigators are now collaborating with us on this project. They have contributed important clinical correlations to our first manuscript.

Anat Erdreich-Epstein, MD, PhD
Children’s Hospital Los Angeles

A GENE THAT IMPROVES BRAIN TUMOR RESPONSE TO THERAPY

The Children’s Center for Cancer and Blood Diseases remains ever grateful for the Concern Foundation’s generous support of the research we conduct and the children and families we serve. It is only through partnerships with philanthropic organizations like Concern that we can achieve our mission to discover cures for devastating pediatric brain tumors while serving the needs of our patients. Our work on PID1 has been generously supported for the past two years in part through funds from Ms. Mimi Feldman and the Concern Foundation.

Specific Aim: Determine which cellular processes contribute to the decreased growth of medulloblastoma cells that have high PID1.

During our first year we reported that medulloblastoma cell lines engineered to express PID1 had decreased colony formation, indicating growth inhibition by PID1. The inhibition was due to both decreased proliferation and increased cell death. Using a mutant of PID1 we found that the growth inhibition was not mediated via its phosphotyrosine binding (PTB) domain, suggesting that the function of PID1 lay in a different domain of the gene to which function has not yet been assigned.

In the second year we tested six mutants of PID1, each comprising a third of PID1, as well as deletion mutants of PID1.

The postdoctoral fellow will build on these findings and continue to dissect the molecular mechanism of PID1. Once the region responsible for the inhibitory effect in PID1 and its function are known, it may be possible to model this knowledge for future therapeutic use.

The work supported by the Concern Foundation and Ms. Mimi Feldman has prompted interactions with two groups of brain tumor researchers from separate institutions, who have access to independent and non-overlapping expression microarray databases of tumors and survival data from patients with medulloblastoma and gliomas. As a result, these investigators are now collaborating with us on this project. They have contributed important clinical correlations to our first manuscript.

Lili Yang, PhD
University of California, Los Angeles

STEM CELL-ENGINEERED INVARIANT NATURAL KILLER T CELLS FOR CANCER IMMUNOTHERAPY

Lili Yang, PhD, was recruited to the UCLA Broad Stem Cell Research Center from Caltech in January 2013. Concern Foundation and one of its community partners, Save the Ta-tas Foundation, provided the much needed resources for Dr. Yang to initiate a project that will establish stem cell-engineered natural killer T cell therapy for cancer.

Our blood is comprised of blood stem cells, including special white blood cells called T cells, which serve as the “foot soldiers” of the immune system, attacking intruders that cause diseases. Among these is a smaller group of cells called invariant natural killer T cells (iNKT), which have a remarkable capacity to mount immediate and powerful responses to disease when activated, much like a special forces unit among the foot soldiers.

Dr. Yang’s project is developing a novel model system to genetically program human blood stem cells to become iNKT cells. With this knowledge, Dr. Yang and colleagues hope to provide a roadmap for future therapies designed to increase the number of iNKT cells in the blood, creating more “special forces” cells and increasing the body’s ability to fight off cancer.

“The potential for iNKT T cell receptor-based gene therapy is very exciting because it is very different from conventional T cell receptor-based gene therapy,” said Dr. Yang. The kind of iNKT T cell receptor gene therapy we are investigating could have universal application, treating many types of cancer and a large group of patients no matter what types of tumor they have. It holds tremendous promise for the future.”

Dr. Yang’s research has made incredible strides at a remarkable pace. As a result of her work funded by Concern, she is a recent recipient of the prestigious $2.3 million NIH Director’s New Innovator Award.
Concern Foundation, with matching funds from Cancer Research Institute (CRI), provides an annual endowment to the Karolinska Institute in Stockholm, Sweden. Under the direction of George Klein, M.D., this grant supported 19 researchers who are developing novel approaches to cancer research in the following four areas.

**AREA A: EPSTEIN-BARR VIRUS (EBV) AND KAPOSI SARCOMA HERPESVIRUS (HHV-8)**

Molecular studies of viral latency and transformation:
- Elena Kashuba
- Surya Pavan
- Suhas Darekar
- Emil Khaibulin
- Liang Wu
- Gyorgy Stuber

**EBV – host cell interactions:**
- Lorand Levente Kis
- Daniel Salamon
- Li Fu Hu

**AREA B: ONCOGENES AND TUMOR SUPPRESSOR GENES**

Myc activation in tumors:
- Nikolay Zinin
- Inga Muller

**Discovery and analysis of new suppressor genes on the short arm of human chromosome 3:**
- Stefan Imreh
- Maria Alimova
- Alecia Viklund
- Patricia Rodriguez
- Elvira Grigorieva

**AREA C: TUMOR IMMUNOLOGY**

- Noemi Nagy
- Harsha Madapura
- Anquan Liu

**AREA D: CYTOTOXIC DRUG SENSITIVITY**

- Gyorgy Stuber

**EBV- Presence of EBV specific T cell responses in infected humanized mice (mice that have been reconstituted with human immune system). Total splenocyte populations (T and B cells) of EBV infected humanized mice were plated with or without the cell inhibitor cyclosporine A (CsA). After 4 weeks, individual wells were photographed to record the size of the growing clumps representing EBV transformed cells that survived the specific T cell control. Growth of the EBV transformed cells occurred when the T cells were inhibited by CsA (right side of the picture), while these EBV infected B cells did not grow in the presence of T cells (control). This growth pattern proves the existence of EBV specific T cells in the spleen.**

**Laszlo & Emilie -** George Klein’s and Laszlo Szekely’s group, working on tumor resistance, particularly the inhibitory activity of normal fibroblasts on tumor cells.

**Co-culture -** The non-inhibitory prostate fibroblasts express smooth-muscle actin (GREEN) both when they are cultured alone and when in co-culture with A549-lung carcinoma cells (PINK nuclei). Both cell types are stained with Hoechst (blue nuclei).

**George & Noemi -** George Klein with Noemi Nagy, senior fellow in Eva Klein’s group. The following illustration exemplifies part of her project: EBV
For over forty years, Concern Foundation has been proud to support the fine work of the Lautenberg Center. This annual endowment is supported by a generous grant from the Ahmanson Foundation. The following page summarizes the incredible work of just two of our funded cancer immunology researchers at the Lautenberg Center.

BELOW ARE THE 14 SCIENTISTS CURRENTLY SUPPORTED BY THE CONCERN FOUNDATION ENDOWMENT:

Rami I. Aqeilan       Ruth Gallily       Moshe Kotler       Michael Steinitz
Michael Baniyash     Ygal Haupt        Ofer Mandelboim    Eitan Yefenof
Yinon Ben Neriah     Shoshana Israel    David Naor         Eli Pikarsky
Shlomo Z. Ben-Sasson  Eli Kedar
Studying the Biology of NK Cells
Professor Ofer Mandelboim

Natural killer (NK) cells are cells of the innate immunity system that are able to kill virus infected cells, tumor cells, parasites and bacteria. The NK cells activity is controlled by inhibitory and activating receptors that bind to specific ligands on their target pathogens or tumors. We are studying the biology of NK cells, the mechanisms used by NK cells to recognize their targets and the counter mechanisms employed by viruses and tumors to escape this NK cell recognition.

I am pleased to report that the past year was very productive and resulted in 18 publications. We studied NK cell function during virus infection and during tumor recognition. We investigated the interactions of NK cells with bacteria. Natural Killer (NK) cells play a central role in the defense against viral infections and in the elimination of transformed cells. The recognition of pathogen-infected and tumor cells is controlled by inhibitory and activating receptors. NK cell populations are found in the blood and also reside in some tissues and traffic to various infected organs through the usage of different chemokines and chemokine receptors. Kaposi’s sarcoma-associated herpes virus (KSHV) is a human virus that has developed numerous sophisticated and versatile strategies to escape the attack of immune cells such as NK cells. Finally we studied basic aspects of NK cells. Three students completed their PhD under my supervision this year.

Characterizing Inflammatory Links in Liver Cancer
Professor Eli Pikarsky

The link between inflammation and cancer is now established, yet the underlying molecular mechanisms are unresolved. As tumors progress, they modulate the inflammatory cells towards a protumorigenic phenotype. We have shown that the inflammatory cells reciprocate by sculpting the parenchymal epithelial cells. I hypothesize that these reciprocal interactions lie at the heart of the link between inflammation and cancer. Hepatocellular carcinoma (HCC) – the most common form of primary liver cancer, is the second leading cause of cancer death worldwide and is a prototype of inflammation induced cancer.

We employ several strategies to analyze the changes that occur in inflammatory cells before and after tumor emergence, based on our preliminary findings showing that changes in inflammatory cells precede tumorigenesis. We are comprehensively mapping the changing inflammatory microenvironment in mouse models of inflammation induced HCC. Using genetic manipulation strategies, coupled to cell isolation techniques we are delineating the molecular cues that mediate these changes and are analyzing the functional role of key mediators of these processes in the malignant process. We have recently characterized a new form of inflammation which is characterized by the presence of focal collections of immune cells. Surprisingly, this form of inflammation promotes cancer growth by hijacking molecules which are secreted by lymphocytes, which are usually associated with anti-tumor responses. This finding could impact immunotherapy of cancer, wherein lymphocytes are usually considered positive mediators of anti-cancer responses.
The 39th Annual Concern Foundation Block Party Fundraiser was held on Saturday, July 13 at Paramount Pictures Studios in Hollywood. The Concern Foundation is proud of raising $1.6 million, which represents a $130,000 increase from the amount raised in 2012.

The 2013 theme, A Salute To Television, honored TV pioneers Ava and Chuck Fries. Hollywood celebrities and classic film and television footage could be seen from all angles of the party.

The New York back lot at Paramount Pictures Studios was transformed into an energized block party where 4,000 guests enjoyed food, drinks and entertainment on four different stages. The Saturday night event showcased nearly 70 restaurants and caterers who provided a “taste” of their culinary specialties. Some of the performers who rocked the night included: Paul McDonald Big Band featuring Tom Nolan, Captain Sugarman and the Space Cadets, and D’City Sound featuring DJ Dwayne. Guests also enjoyed interactive activities like games, photo booths, and live and silent auctions.

Los Angeles magazine, the media partner for 8 years running, outfitted the Best of LA® street with casino style gaming and cocktails sponsored by TANQUERAY®, the new 2014 Cadillac CTS and ATS, body assessments and massages from Equinox, Vdara Hotel & Spa photo booth, Stella Artois Beer Garden, artisan coffee and tea from Grand Avenue Coffee and samples from Clif and Luna bar. With the support of these sponsors, Los Angeles magazine donated $25,000 to Concern Foundation.

Team Concern Runs Los Angeles and New York City

2013 was Concern Foundation’s 4th consecutive year as an Official Charity of the ASICS LA Marathon.

After the unfortunate cancellation of the New York City Marathon due to Hurricane Sandy in late 2012, Team Concern came back stronger than ever in its fourth consecutive year as an Official Charity of the ASICS LA Marathon.

Collectively, Team Concern’s 75 runners and walkers raised more than $110,000 for cancer research. The team, along with all 25,000 race participants, were cheered on by loyal Concern supporters and volunteers at the Concern Cheer Zone in Beverly Hills, at mile 16 of the LA Marathon.

Since 2010, more than 200 Team Concern participants have crossed the finish line of the full Marathon, 2-person Charity Relay and LA 5k, and have raised well over $350,000 for cancer in the quest to “Conquer Cancer One Mile at a Time”.

Team Concern was thrilled to also be named an Official Charity of the ING NYC Marathon—the Largest Marathon in the World—for the 3rd straight year.

In 2013 our 14 participants ran 26.2 Miles through all 5 boroughs of New York City representing Concern Foundation. Completing the New York City Marathon is a tremendous feat that many people dream of their entire lives. This achievement, along with reaching over $44,000 in fundraising support, made Concern Foundation so proud of Team Concern.
COMMUNITY EVENTS

Holiday Party at Paramount Pictures

Concern threw its 26th Annual Christmas Event for pediatric cancer patients and their families at Paramount Studios to the theme of Rock ‘n’ Roll ‘50s!

More than 130 pediatric cancer patients were in attendance, many dressed in full 50’s attire: girls in cute poodle skirts and boys in tough leather jackets. In total, 600 guests excitedly anticipated the day’s activities. The festivities kicked off with the screening of the popular hit Grease. Once the movie ended and the screening room doors opened, the kids were welcomed into a 50’s style cafe filled with candy, hula hoops, and dancing (or should we say “jiving”?) with a live DJ and his dance crew.

Paramount was turned into a winter wonderland where Santa arrived early from the North Pole to deliver bountiful gifts to each family. The kids decorated cookies provided by Cookies for a Cause, made their own ice cream confections with Dandy Don’s, and felt extra-special with pampering from Beauty Bus Foundation.

The evening was lit by twinkle lights while a giant Christmas tree surrounded by presents stood prominently in the background as children opened their gifts with huge smiles on their faces. It was a magical event and the perfect way to ring in the Holiday Season and close a wonderfully successful year.

Concern Foundation’s Annual “Day for Kids” at Universal Studios Hollywood

On September 29th, Concern Foundation treated 300 pediatric cancer patients and guests to a fun-filled day at Universal Studios. An annual partnership between Concern and Universal, we are so thankful to Universal Studios for providing a private tram tour for all of our guests, a delicious catered lunch in the Globe Theater and front of the line passes so everyone could skip those long lines and feel like VIP for the entire day. We are also grateful to all of Concern’s awesome volunteers who lead groups of kids of all different ages to help them enjoy this special day!
## ASSETS

<table>
<thead>
<tr>
<th>Asset</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$2,318,829</td>
</tr>
<tr>
<td>Investments</td>
<td>2,578,273</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>8,848</td>
</tr>
<tr>
<td>Pledges receivable, net</td>
<td>640,553</td>
</tr>
<tr>
<td>Beneficial interest in charitable remainder trusts</td>
<td>259,238</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>6,231</td>
</tr>
<tr>
<td>Other assets</td>
<td>54,278</td>
</tr>
</tbody>
</table>

**Total assets** $5,866,250

## LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th>Liability</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grants payable</td>
<td>$510,000</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>33,468</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>640,553</td>
</tr>
</tbody>
</table>

**Total liabilities** $1,184,021

## Commitments

### Net assets

<table>
<thead>
<tr>
<th>Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td></td>
</tr>
<tr>
<td>Undesignated</td>
<td>1,872,471</td>
</tr>
<tr>
<td>Board-designated</td>
<td>600,000</td>
</tr>
</tbody>
</table>

**Total unrestricted** $2,472,471

<table>
<thead>
<tr>
<th>Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temporarily restricted</td>
<td>289,386</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>1,920,372</td>
</tr>
</tbody>
</table>

**Total net assets** $4,682,229

**Total liabilities and net assets** $5,866,250
## Concern Foundation and Subsidiary
### (A Nonprofit Organization)
#### Consolidated Statement of Activities

For the Year Ended December 31, 2013

<table>
<thead>
<tr>
<th>Revenue and support</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$ 2,322,139</td>
<td>$ 91,500</td>
<td>-</td>
<td>$ 2,413,639</td>
</tr>
<tr>
<td>Special events, net</td>
<td>1,008,272</td>
<td>50,000</td>
<td>-</td>
<td>1,058,272</td>
</tr>
<tr>
<td>Campaign</td>
<td>29,852</td>
<td>-</td>
<td>-</td>
<td>29,852</td>
</tr>
<tr>
<td>Investment income (loss)</td>
<td>(29,459)</td>
<td>37,408</td>
<td>-</td>
<td>7,949</td>
</tr>
<tr>
<td>Change in value of charitable remainder trusts</td>
<td>-</td>
<td>20,850</td>
<td>-</td>
<td>20,850</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>176,585</td>
<td>(176,585)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Satisfaction of temporary restrictions</td>
<td>176,585</td>
<td>(176,585)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total revenue and support</td>
<td>3,507,380</td>
<td>23,173</td>
<td>-</td>
<td>3,530,562</td>
</tr>
</tbody>
</table>

### Functional expenses

| Program services | 1,572,549 | - | - | 1,572,549 |
| Management and general | 67,846 | - | - | 67,846 |
| Fundraising | 213,881 | - | - | 213,881 |

| Total functional expenses | 1,854,276 | - | - | 1,854,276 |

### Change in net assets

| Net assets, beginning of year | 810,358 | 266,213 | 1,920,372 | 3,005,943 |
| Net assets, end of year | $ 2,472,471 | $ 289,386 | $ 1,920,372 | $ 4,682,229 |
2013 CONCERN FOUNDATION EXECUTIVE BOARD

Lexy and John Carroll, Co-Chairs (2012-2013)
Derek Alpert, President
Marc Lauter, Chief Financial Officer
Michael Firestein, Secretary/Legal Counsel
Bob Goldman, Vice President/Audit Committee Chair
Jim Hausberg, Finance Committee Chair

Anne Barnett
Bill Barnett
Harvey Beesen
Carla Daly
Nancy Eisenstadt
David Entin
Michael Firestein
Steve Fortner
Steve Freed
Jim Freedman
Andrea Friedman
Lorene Goldman
Jackie Gottlieb
Stanley Gottlieb
Max Sisson Liszt
Marc Luber
Ian Metrose
Lauri Metrose
June Miller Richards

Frank Mottek
Jessica Nicastro
Debbie Powell
Joyce Powell
Larry Powell
Rick Powell
Laurie Resch
Marc Schultz
Bill Schwartz
Lisi Teller
Steve Teller
Bob Thom
Steve Ullman
Briana Vickers
Scott Vickers
Myrna Zimmerman
Stan Zimmerman
GET INVOLVED WITH CONCERN FOUNDATION

Concern Foundation has raised over $57 Million to fund cancer research through donations from individuals like yourself! Help us **CONquer can** **CER Now**.

- Make a monetary donation today.
- Become an Annual Sponsor and enjoy sponsorship benefits
- Send a tribute in honor or in memory of someone special
- Be a part of our signature Block Party fund raising event
- Start your own fundraiser
- Be a part of Team Concern by participating in the LA marathon or another athletic event or activity of your choice
- Take steps to create a planned gift
- Donate your time and expertise by volunteering
- Get your place of business involved and become a community partner or corporate sponsor
- Help spread the word about Concern Foundation

Each year, **14 million men, women, and children worldwide** are diagnosed with some type of cancer. Continued research to find better, smarter, more effective treatments is urgently needed. Only with your help can we continue to fund innovative research and bring breakthrough treatments and “cures” to more cancer patients.
Please consider Concern Foundation in your estate plan.